Cerebrospinal fluid leak after brain tumor surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational project will collect clinical and surgical data from adult patients undergoing elective supratentorial craniotomy for intracranial tumors at the Medical University of Warsaw. Patients having revision or emergency procedures are excluded to focus on primary planned tumor operations. Postoperative courses will be followed to document occurrences of cerebrospinal fluid leakage, wound healing problems, infection, reoperations, and any delays to adjuvant therapies such as radiotherapy or chemotherapy. The dataset will be analyzed to describe incidence, timing, and potential risk factors associated with leakage in this specific surgical population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female at least 18 years old
* Qualified for a craniotomy due to supratentorial intracranial tumor

Exclusion Criteria:

* Revision surgery due to recurrent brain tumor
* Emergency neurosurgical procedure

Where it's running

• Department of Neurosurgery of Medical Univeristy of Warsaw
  Warsaw, Poland Recruiting

Study contacts

• Principal investigator: Michal Senger, M.D. — Department of Neurosurgery, Medical University of Warsaw, Warsaw, Poland
• Study coordinator: Michal Senger, M.D.
• Email: michal.senger@wum.edu.pl
• Phone: +48 791 760 040

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Skin closure after brain tumor surgery: running absorbable versus interrupted non-absorbable sutures

  This will test whether absorbable running intradermal sutures or non-absorbable interrupted transdermal sutures produce better wound healing after craniotomy in adults with supratentorial brain tumors.

  Recruiting Medical University of Warsaw · Warsaw, Masovian Voivodeship · NCT07413796

• Pharmacoscopy-guided treatment for refractory brain tumors

  This trial tests whether personalized drug testing on a patient’s tumor cells can guide treatment choices for adults with hard-to-treat brain cancers like glioblastoma.

  Recruiting Phase 2 University of Zurich · Basel, Basel-Landschaft and 2 other locations · NCT06804655

• Combining TIL Therapy and Pembrolizumab for Advanced Brain Cancer

  This study is testing a new treatment that combines a type of immune therapy using patients' own tumor cells with Pembrolizumab to see if it helps people with advanced brain cancer feel better and live longer.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT06640582

• YN003 injection in glioma patients

  This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.

  Recruiting at 2 sites Phase 1 Beijing Inno Medicine Co., Ltd. · Los Angeles, California and 4 other locations · NCT07929909

• Brain connectome project in adults with brain glioma undergoing surgery

  This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.

  Recruiting Northwell Health · New York, New York · NCT07927595

• Sitagliptin plus bevacizumab for recurrent grade 4 glioma

  This study tests whether adding sitagliptin to bevacizumab can help people whose recurrent glioblastoma or other grade 4 gliomas respond to treatment and to find a safe dose when used with bevacizumab.

  Recruiting Phase 1 University of Iowa · Iowa City, Iowa · NCT07541781

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.